If you enjoy this content, please share it with a colleague
RELATED CONTENT
November 12, 2009 – IBA (Ion Beam Applications S.A.) introduced a smaller, two-room, and lower-cost footprint for traditional Proton Therapy centers for cancer treatment, called the Proteus Nano, at the 51st Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Nov. 1–5, 2009, at McCormick Place West in Chicago, Ill.
September 21, 2009 – IBA (Ion Beam Applications S.A.), a provider of PET radiopharmaceuticals, and Aposense Ltd., a developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced an exclusive collaboration agreement for commercializing Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis.
February 23, 2009 - An advance in the way protons are delivered at the University of Florida Proton Therapy Institute — called uniform scanning — reportedly enable physicians to treat tumors that are deeper in the body, tumors that are very large and tumors that are situated closer to vital organs.
December 23, 2008 - The FDA cleared Ion Beam Applications’ (IBA) cyclotron-based integrated commercial proton therapy system with pencil beam scanning (PBS), a delivery method that allows for precise dose delivery by its proton therapy system.
July 25, 2007 – The IBA business unit, IBA Particle Therapy, recently announced the release of its full-size Universal Nozzle alpha that reportedly allows treatment planners and clinicians to expand capabilities in choosing the optimal treatment beam delivery mode for each patient.
July 25, 2007 – The IBA business unit, IBA Particle Therapy, recently announced the release of its full-size Universal ...